Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Clin Pharmacol Ther. 2019 Dec 31;107(5):1200–1208. doi: 10.1002/cpt.1714

Figure 1.

Figure 1.

Study Design. Study periods are shown in days 1–4. Study interventions are (1) “T” test +PRO Treatment = 2 g PRO + 600 mg TDF/ 400 mg FTC at t=0 h or (2) “C” control IPERGAY Treatment = 600 mg TDF/ 400 mg FTC at t=0 h; 300 mg TDF/ 200 mg FTC at t= 24, 48 h. Treatment regimens were separated by ≥ 6 weeks wash-out period.